Biotech Investor Shareholders Approve Buy Of Rival's Assets
RTW Biotech Opportunities Ltd. said on Tuesday that it has won approval from its shareholders to buy rival Arix's assets, worth nearly $284 million excluding liabilities, in a deal guided by...To view the full article, register now.
Already a subscriber? Click here to view full article